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Summary
Background Use of aggressive and invasive interventions is
more common in the USA than in other countries. We have
compared use of resources for patients with cardiogenic
shock after myocardial infarction in the USA and in other
countries, and assessed the association between use of
resources and clinical outcomes.
Methods We analysed data for patients with cardiogenic
shock after myocardial infarction who were enrolled in the
GUSTO-I trial (1891 treated in the USA, 1081 treated in
other countries) . Patients were randomly assigned
combinations of streptokinase, heparin, and accelerated
tissue-plasminogen activator (t-PA), then decisions about
further interventions were left to the discretion of the
attending physician. The interventions included in our
analysis were: pulmonary-artery catheterisation, cardiac
catheterisation, intravenous inotropic agents, ventilatory
support, intra-aortic balloon counterpulsation ( IABP),
percutaneous transluminal coronary angioplasty (PTCA),
and coronary bypass graft surgery (CABG). The primary
outcome measure was death from any cause at 30 days of
follow-up.
Findings Patients who were treated in the USA were
significantly younger than those treated elsewhere
(median 68 [IQR 59–75] vs 70 [62–76], p<0·001), a
smaller proportion had anterior infarction (49 vs 53%,
p<0·001), and they had a shorter time to treatment (mean
3·1 vs 3·3 h, p<0·001). Aggressive diagnostic and
therapeutic procedures were used more commonly in the
USA than in the other countries: cardiac catheterisation
(58 vs 23%); IABP (35 vs 7%); right-heart catheterisation
(57 vs 22%); and ventilatory support (54 vs 38%). 483
(26%) of the patients treated in the USA underwent PTCA,
compared with 82 (8%) patients in other countries. Patients
who underwent revascularisation had better survival in all
countries. Adjusted 30-day mortality was significantly lower
among patients treated in the USA than among those
treated elsewhere (50 vs 66%, p<0·001). The difference in
mortality remained at 1 year—56% of patients treated in
the USA died versus 70% of patients treated elsewhere
(hazard ratio 0·69 [95% CI 0·63–0·75], p<0·001).
Interpretation 30-day and 1-year mortality was significantly
lower among patients treated in the USA than among those
treated in other countries. This difference in mortality may
be due to the greater use of invasive diagnostic and
therapeutic interventions in the USA.
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Introduction
Use of resources for treatment of acute myocardial
infarction varies greatly throughout the world.1–6 The
more invasive and costly procedures, such as cardiac
catheterisation, percutaneous transluminal coronary
angioplasty (PTCA), and coronary bypass graft surgery
(CABG), are used more commonly in the USA than in
other countries.5,6 The extent to which this difference in
use affects outcome, particularly in high-risk patients who
may have the most to gain from effective treatment
strategies, is not clear.
Patients with acute myocardial infarction who are at
greater risk of death are those with cardiogenic shock.7–9
In the GUSTO-I trial of 41 021 patients, cardiogenic
shock was identified on a prospectively collected data
form in 2972 (7·2%) patients. These patients had a
30-day mortality of 55% and accounted for 59% of all
deaths in the trial.7
We have compared use of resources for patients with
cardiogenic shock in the USA and in other countries, and
assessed the association between use of resources and
clinical outcome.
Methods
The GUSTO-I trial has been previously described in detail.10,11
41 021 patients from the USA and 14 other countries who had
symptoms of acute myocardial infarction and ST-segment
elevation were enrolled and randomly assigned one of four
thrombolytic regimens: 1·5 million units of streptokinase and
subcutaneous heparin; 1·5 million units of streptokinase and
intravenous heparin; accelerated tissue-plasminogen activator
(t-PA) and intravenous heparin; or a combination of strepto-
kinase, t-PA, and intravenous heparin. The primary endpoint was
death from any cause by 30 days of follow-up. All patients gave
informed consent to take part in the trial. The study protocol was
approved by the institutional review board at each hospital.
Patients who had cardiogenic shock were a predefined
subgroup for whom we used additional prospectively designed
data-collection forms. The GUSTO protocol defined cardiogenic
shock as a systolic blood pressure of 90 mm Hg or less for more
than 1 h despite a fluid challenge, together with signs of
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regression to assess the effect of geographical location on 30-day
mortality.
For the analysis of the effect of intervention on 30-day
mortality by geographical location, we adjusted for those patients
who did not survive long enough to receive an intervention. If the
non-intervention groups were credited with all these early events,
the beneficial effect of an intervention would be unfairly inflated.
Thus, we used a time-dependent Cox proportional hazards model
of 30-day mortality, which treated patients as non-procedure
patients until the start of an intervention. The types of
intervention included as time-dependent covariates in this
modelling were PTCA, CABG, cardiac catheterisation, and
IABP. We excluded right-heart catheterisation and ventilator use
from time-dependent modelling because the date of the use of
these procedures relative to cardiogenic shock was not
known. Similarly, we used time-dependent modelling to assess
the effect on 1-year mortality of USA versus non-USA
location, according to use of revascularisation. All p values are
two tailed. 
Results
Of the 40 736 patients, for whom complete data on shock
were available, 22 883 (56·2%) were treated in the USA
and 17 853 (43·8%) in other countries. Cardiogenic shock
occurred in a greater proportion of patients treated in the
USA than in those treated elsewhere (1891 [8·3%] vs
1081 [6·1%], p<0·001). In most cases, cardiogenic shock
developed after admission; in the USA and the other
countries only 0·8% and 0·7% of patients, respectively,
had shock on admission.
There were significant differences in baseline
characteristics of patients with cardiogenic shock
between those treated in the USA and those treated
elsewhere (table 1). Patients treated in the USA were
significantly younger than those treated in other countries,
a smaller proportion had anterior myocardial infarction,
and they had a slightly shorter time to treatment. A greater
proportion of patients treated in the USA than those
treated elsewhere had undergone CABG previously.
hypoperfusion or a cardiac index of 2·2 L min1 m2 or less,
judged by the physician to be secondary to cardiac dysfunction.
The definition of shock also included those patients in whom
systolic blood pressure increased to more than 90 mm Hg within
1 h of administration of inotropic agents.
Decisions about further interventions (ie, diagnostic
procedures and adjunctive therapies) were left to the discretion of
the attending physician. We compared use of interventions at
centres in the USA and in other countries. The procedures and
therapies included in our analysis were: pulmonary-artery
catheterisation; cardiac catheterisation; intravenous inotropic
agents; ventilatory support; intra-aortic balloon counterpulsation
(IABP); PTCA; and CABG.
We assessed the potential effect of differences in the baseline
characteristics of patients on outcome. For this analysis we
selected those characteristics found to be the most important
factors associated with mortality in the GUSTO-I trial: age,
systolic blood pressure, Killip class on entry, heart rate, location
of myocardial infarction (anterior vs inferior), history of previous
infarction, height, weight, time to treatment, diabetes mellitus,
history of cigarette smoking, current smoking, previous CABG,
history of hypertension, and previous cerebrovascular disease. Lee
at al12 have shown that five of these factors in the entire GUSTO-
I trial—age, systolic blood pressure, Killip class on entry, heart
rate, and location of infarction—accounted for 90% of the ability
of the model to predict outcome. In addition to these significant
factors, the effects of ethnic origin, sex, diastolic blood pressure,
previous PTCA, and previous angina were also analysed.
We used standard contingency table 2 tests or Fisher’s exact
tests to assess geographical differences in intervention and
outcome between groups of patients defined by categorical
variables. The Wilcoxon rank-sum test was used for analysis of
continuous variables. After adjustment for the five significant
factors identified by Lee et al,12 we used multivariate logistic
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USA Other countries p
(n=1891) (n=1081)
Median (IQR; range) 68 (59–75; 30–108) 70 (62–76; 30–90) <0·001
age in years
Median (IQR) systolic 114 (97–130) 120 (100–135) <0·001
blood pressure (mm Hg)
Baseline Killip class
I 1240 (66%) 596 (55%) <0·001
II 350 (19%) 281 (26%)
III 91 (5%) 75 (7%)
IV 188 (10%) 127 (12%)
Median (IQR) heart rate 80 (66–96) 80 (67–98) 0·255
(bpm)
Location of myocardial infarction
Anterior 930 (49%) 573 (53%) <0·001
Inferior 917 (49%) 464 (43%)
No MI 2 (<1%) 1 (<1%)
Other 35 (2%) 40 (4%)
Previous myocardial 463 (25%) 280 (26%) 0·469
infarction
Median (IQR) height (cm) 170 (163–178) 168 (160–175) <0·001
Time to treatment (h)
Mean (SD) 3·1 (1·8) 3·3 (1·6) <0·001
Median (IQR) 3 (2–4) 3 (2–4)
Range 0·1–23·1 0·2–17·5
Diabetes mellitus 374 (20%) 184 (17%) 0·061
Median (IQR) weight (kg) 76 (66–87) 72 (65–80) <0·001
Smoking status
Current 647 (35%) 329 (31%) 0·020
Ever 1171 (65%) 581 (56%) <0·001
Previous CABG 146 (8%) 47 (4%) <0·001
History of hypertension 864 (46%) 414 (39%) <0·001
Previous cerebrovascular 78 (4%) 38 (4%) 0·398
disease
bpm=beats per min.
Table 1: Baseline characteristics of patients with cardiogenic
shock
Intervention USA Other countries p*
(n=1891) (n=1081)
Cardiac catheterisation 1092 (58%) 253 (23%) <0·001
IABP 652 (35%) 80 (7%) <0·001
Right-heart catheterisation 1074 (57%) 236 (22%) <0·001
Ventilatory support 1021 (54%) 405 (38%) <0·001
CABG 295 (16%) 43 (4%) <0·001
PTCA 483 (26%) 82 (8%) <0·001
Inotropic agent 1850 (98%) 998 (93%) <0·001
β-blocker 1024 (54%) 410 (38%) <0·001
Aspirin 1768 (94%) 1016 (94%) 0·610
*Data on types of interventions used for some patients were not available; differences
between geographical locations were assessed only for patients whose data were
available.
Table 2: Use of interventions and medications by geographical
location
Intervention USA Other countries p
All patients
n 1891 1081
Deaths by 30 days 936 (50%) 711 (66%) <0·001
CABG
n 295 43 <0·001
Deaths by 30 days 81 (27%) 17 (38%) 0·722*
PTCA
n 483 82 <0·001
Deaths by 30 days 84 (30%) 39 (48%) 0·090*
*Value for differential effect of intervention in patients from USA vs patients from
other countries.
Table 3: Outcome of cardiogenic shock by 30 days and type of
revascularisation used
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Use of aggressive diagnostic and therapeutic
interventions was more common in the USA than in
the other countries (table 2). Pulmonary-artery
catheterisation, cardiac catheterisation, IABP, PTCA, and
CABG were done significantly more frequently in the
USA than in other countries (p<0·001, table 2). Similarly,
ventilatory support was more widely used in the USA than
elsewhere (p<0·001).
Differences in the use of medication between the USA
and the other countries were less consistent (table 2). As
previously reported in the GUSTO-I trial,10 intravenous or
oral -blockers were more commonly administered to
patients with cardiogenic shock in the USA than in the
other countries. Intravenous inotropic agents were used
commonly in the USA and other countries, but use was
significantly more frequent in the USA. There was no
geographical difference in the frequency of aspirin use.
The 30-day mortality rate among patients with
cardiogenic shock was significantly lower in the USA than
in the other countries (50 vs 66%, p<0·001; table 3). After
adjustment for the baseline characteristics of patients,
those treated in the USA had significantly lower mortality
than patients treated elsewhere. In the multivariate
analysis, only two factors—age and systolic blood
pressure—were more strongly associated with increased
mortality than was geographical location (tables 4, 5).
Adjustment for all potential baseline factors did not
attenuate the association between treatment in the USA
and improved outcome (p <0·0001). This finding did not
change after adjustment for both interventions and the
significant baseline factors (p <0·001).
30-day mortality after revascularisation was lower
among patients with cardiogenic shock treated in the USA
than among those treated elsewhere. After PTCA, there
was a significant difference in 30-day mortality between
the USA and the other countries (table 3). In patients who
underwent CABG, 30-day mortality was 27% in the USA
and 38% elsewhere; however this difference was not
significant (p=0·722).
Table 6 shows mortality at 1 year. The unadjusted
1-year survival rate was higher among patients treated in
the USA than among those treated elsewhere (44 vs 30%,
p<0·001). In all countries, mortality at 1 year was lower
for patients who underwent PTCA (p<0·001). By
contrast, there was no significant difference in unadjusted
1-year mortality between patients who did and patients
who did not undergo CABG (p=0·553).
After adjustment for baseline factors that had a
significant effect on outcome, patients treated in the USA
had significantly lower 1-year mortality than those treated
elsewhere (p<0·001, table 6). Similarly, the adjusted
1-year mortality was lower in patients who had PTCA
than in those who did not (p<0·001), but CABG did not
significantly affect the adjusted 1-year mortality
(p=0·445). Overall, the outcome for patients with
cardiogenic shock was significantly better at 1 year in the
USA than in the other countries, irrespective of whether
revascularisation had been done. This finding did not
change after adjustment for revascularisation (p<0·001).
Discussion
This analysis shows that the use and outcome of aggressive
and invasive interventions for patients with acute
myocardial infarction complicated by cardiogenic shock
differed significantly between the USA and other
countries. Patients treated in the USA had significantly
lower mortality at 30 days and 1 year than patients who
were treated in other countries.
Previous studies have reported differences in countries’
assessment, treatment, and outcome for patients with
myocardial infarction.1,3–5 Among the 13 countries
included in Barbash and colleagues’ study,3 30-day
mortality ranged from 4·2% to 14·8%, but differences in
baseline characteristics between countries did not account
for the geographical differences in mortality. The
investigators suggested different countries’ use of
adjunctive post-thrombolytic treatment strategies together
with genetic and environmental factors might modify the
risk of myocardial infarction.
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Predictor χ2, p Predictor χ2, p
Age 104, <0·001 Time to treatment 10, <0·002
SBP 54, <0·001 Height 11, 0·025
USA vs non-USA 51, <0·001 Previous CABG 4, 0·047
MI location 26, <0·001 AgeKillip 4, 0·286
Baseline Killip 25, <0·001 Treatment 3, 0·392
Smoking 23, <0·001 Previous CVD 0·1, 0·805
Pulse 21, <0·001 Hypertension <0·01, 0·949
Previous MI 20, <0·001 Weight <0·01, 0·996
Diabetes 17, <0·001
SBP=systolic blood pressure; MI=myocardial infarction; CVD=cerebrovascular disease.
Table 4: 30-day mortality model for patients with cardiogenic
shock by baseline characteristics
Predictor χ2, p Predictor χ2, p
SBP 88, <0·001 Time to treatment 9, 0·003
Age 81, <0·001 Diabetes 9, 0·004
USA vs non-USA 48, <0·001 Height 9, 0·050
Baseline Killip 26, <0·001 Previous CABG 7, 0·009
MI location 24, <0·001 PTCA 3, 0·078
Pulse 22, <0·001 Treatment 2, 0·658
AgeKillip 18, <0·001 CABG 0·9, 0·343
Smoking 16, <0·001 Hypertension 0·4, 0·551
CC 15, <0·001 Weight 0·2, 0·676
Previous MI 12, <0·001 Previous CVD 0·01, 0·927
IABP 9, 0·002
SBP=systolic blood pressure; MI=myocardial infarction;CVD=cerebrovascular disease;
CC=cardiac catheterisation.
Table 5: 30-day mortality model for patients with cardiogenic
shock by baseline characteristics and type of intervention
1-year mortality
Unadjusted hazard ratio (95% CI) p Adjusted hazard ratio (95% CI)* p
Single-factor comparisons
USA vs other countries 0·69 (0·63–0·75) <0·001 0·70 (0·64–0·78) <0·001
PTCA vs no PTCA 0·67 (0·58–0·78) <0·001 0·81 (0·70–0·94) <0·005
CABG vs no CABG 0·95 (0·78–1·14) 0·553 1·08 (0·89–1·30) 0·445
Multiple-factor comparisons
USA, revascularisation 0·59 (0·45–0·79) <0·001 0·55 (0·41–0·73) <0·001
Other countries, revascularisation 0·95 (0·73–1·24) 0·707 1·21 (0·92–1·58) 0·168
USA, no revascularisation 0·73 (0·66–-0·81) <0·001 0·73 (0·66–0·82) <0·001
Other countries, no revascularisation† 1·00 1·00
*Adjusted for baseline characteristics of patients with a significant effect on 30-day mortality. †Reference group for multiple-factor comparisons.
Table 6: 1-year mortality
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Mark and colleagues5 assessed the use of medical
resources and outcome for 2600 patients in the USA and
400 patients in Canada who were randomly selected from
the GUSTO trial. That study showed no significant
difference in 30-day survival between countries (93·0% for
the USA vs 92·4% for Canada, p=0·33). However, after
adjustment for baseline clinical characteristics associated
with mortality, patients from the USA had significantly
better survival than Canadian patients (p=0·02). In
addition, coronary angiography, coronary angioplasty, and
bypass surgery were used more frequently in the USA than
in Canada. Whether this difference in resource
consumption accounted for the small difference in 30-day
mortality was not clear. Van de Werf and colleagues4
showed that more invasive procedures were done in the
USA than in the other countries in the GUSTO trial, but
that this difference was associated with only a small
decrease in short-term mortality.
We found small but significant differences in baseline
clinical characteristics of patients with cardiogenic shock
between those treated in the USA and those treated
elsewhere. However, these differences did not fully
account for the significant difference in 30-day mortality.
Indeed, the difference remained after adjustment for the
baseline characteristics. In our multivariate analysis, age
and systolic blood pressure were the only factors more
strongly associated than geographical location with
increased mortality. Even after adjustment for all baseline
characteristics of patients, those treated in the USA had
sigificantly lower mortality at 30 days (p<0·0001). This
difference in mortality persisted at 1 year, even after
adjustment for differences in revascularisation procedures.
Our study showed that patients with cardiogenic shock
in the USA undergo more aggressive interventions, both
diagnostic (eg, cardiac catheterisation) and therapeutic
(eg, IABP, PTCA, CABG), more frequently than do
patients in other countries. However, we were not able to
find out whether the lower 30-day mortality in patients
treated in the USA reflected selection bias or the benefits
of these aggressive adjunctive therapies. Hochman and
colleagues8 examined whether selection bias affected
mortality in patients treated for cardiogenic shock, and
found that patients selected to undergo catheterisation
had a lower mortality than those who were not
selected for this procedure, irrespective of whether
revascularisation was done.8 Since the use of resources was
not mandated by the GUSTO protocol but left to the
discretion of the attending physician, differences in
interventions and outcome may partly reflect the facilities
available at different hospitals. In addition, the attitudes of
patients, physicians, and society towards treatment for
patients with emergency medical conditions may also be
important factors.
We cannot say for certain that the difference in survival
between the USA and other countries was the result of
more aggressive treatment strategies. In our subgroup of
patients with cardiogenic shock, the early mortality rate
was high. Thus, many patients did not survive long
enough to receive any intervention. Although we used
time-dependent modelling to avoid inflating the beneficial
effect of a procedure, this model may not have fully
compensated for the large number of early deaths. Bias in
the selection of patients who received more aggressive
interventions could have had a substantial effect on the
differences in mortality. Nonetheless, several retrospective
studies have shown that early revascularisation is
associated with better outcome.13–16 In the entire GUSTO-
I trial, the mortality of patients who developed cardiogenic
shock and were treated with PTCA was 32%, compared
with 61% in patients who did not undergo PTCA.7 Other
treatments such as the use of IABP could also have been
important.
Although cardiogenic shock was defined at the start of
GUSTO-I by specific criteria, this definition is somewhat
subjective because it depends on how closely patients were
monitored and the clinical judgments made about the
cause of hypotension. Thus, closer monitoring of patients
in the USA could have identified patients earlier in the
course of shock, and thereby affected outcome. In
addition, differences in selection criteria for more
aggressive treatment strategies could have affected
outcome.
This study was funded by Bayer (New York, USA), CIBA-Corning
(Medfield, Massachusetts), Genentech (South San Francisco, California),
ICI Pharmaceuticals (Wilmington, Delaware), and Sanofi Pharmaceuticals
(Paris, France). 
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